What are Pyruvate dehydrogenase kinase inhibitor drugs?

Pyruvate dehydrogenase kinase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PDK (Pyruvate dehydrogenase kinase)). 0 are currently marketed, with 3 more in clinical development.

Pyruvate dehydrogenase kinase inhibitor

0 marketed 3 in Phase 3

This page covers all Pyruvate dehydrogenase kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PDK (Pyruvate dehydrogenase kinase), PDK (pyruvate dehydrogenase kinase), Pyruvate dehydrogenase kinase (PDK).

Targets

PDK (Pyruvate dehydrogenase kinase) · PDK (pyruvate dehydrogenase kinase) · Pyruvate dehydrogenase kinase (PDK)

Phase 3 pipeline (3)

Etavopivat B · Novo Nordisk A/S · Hematology/Rare Blood Disorders
Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.
Etavopivat C · Novo Nordisk A/S · Hematology/Rare Blood Disorders
Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.
Dichloroacetate (DCA) · University of Florida · Oncology
Dichloroacetate inhibits pyruvate dehydrogenase kinase, shifting cellular metabolism from glycolysis toward oxidative phosphorylation.